These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34198742)

  • 1. Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success.
    Michelozzi IM; Kirtsios E; Giustacchini A
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34198742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden.
    Biondi M; Tettamanti S; Galimberti S; Cerina B; Tomasoni C; Piazza R; Donsante S; Bido S; Perriello VM; Broccoli V; Doni A; Dazzi F; Mantovani A; Dotti G; Biondi A; Pievani A; Serafini M
    Blood; 2023 May; 141(21):2587-2598. PubMed ID: 36787509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them.
    Vanhooren J; Dobbelaere R; Derpoorter C; Deneweth L; Van Camp L; Uyttebroeck A; De Moerloose B; Lammens T
    Hemasphere; 2023 Sep; 7(9):e937. PubMed ID: 37674860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy.
    Epperly R; Gottschalk S; Velasquez MP
    Front Oncol; 2020; 10():262. PubMed ID: 32185132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia.
    Yu W; Zhang H; Yuan Y; Tang J; Chen X; Liu T; Zhao X
    Front Cell Dev Biol; 2022; 10():928140. PubMed ID: 35990606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.
    Zha C; Song J; Wan M; Lin X; He X; Wu M; Huang R
    Ther Adv Hematol; 2024; 15():20406207241263489. PubMed ID: 39050113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.
    Guijarro-Albaladejo B; Marrero-Cepeda C; Rodríguez-Arbolí E; Sierro-Martínez B; Pérez-Simón JA; García-Guerrero E
    Front Cell Dev Biol; 2024; 12():1376554. PubMed ID: 38694825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
    Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
    Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.
    Urs AP; Goda C; Kulkarni R
    Ann Transl Med; 2024 Aug; 12(4):63. PubMed ID: 39118939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche.
    Alberti G; Arsuffi C; Pievani A; Salerno D; Mantegazza F; Dazzi F; Biondi A; Tettamanti S; Serafini M
    Front Immunol; 2023; 14():1192333. PubMed ID: 37304257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy for T-ALL and AML.
    Wei W; Yang D; Chen X; Liang D; Zou L; Zhao X
    Front Oncol; 2022; 12():967754. PubMed ID: 36523990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.
    Thakral D; Gupta R; Khan A
    Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
    Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
    Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.